RATIONALE: Information on the clinical profile of CIU/CSU in adolescents is limited. Baseline characteristics and demographics of an adolescent subgroup of CIU/CSU patients enrolled in randomized, placebo-controlled omalizumab trials are evaluated. METHODS: This is a post-hoc descriptive analysis of pooled baseline data from three omalizumab trials in CIU/CSU patients who remained symptomatic despite H 1 -antihistamine treatment [and H 2 -antihistamines and/or leukotriene receptor antagonists (LTRA) in one study]. Demographics and disease characteristics are summarized for overall and for adolescent patients (> _12 to <18 years).
RESULTS: Of 975 patients [mean (standard deviation; SD) age, 42.3 (14.1) years], 39 were adolescents [15.1 (1.5) years]. Most patients were female (overall, 73.4%; adolescents, 69.2%) and white (85.4%; 84.6%), with a mean BMI (SD) of 29.6 (7.3) and 24.4 (4.7) kg/m 2 , respectively. A CU index test (functional anti-FcεR) was positive in 28.5% overall and 17.9% of adolescents. Mean urticaria activity score over 7 days (SD) was 30.9 (6.7) overall and 28.6 (5.7) for adolescents; weekly itch severity score, 14.1 (3.6) and 13.3 (3.4); weekly number of hives score, 16.8 (4.3) and 15.3 (4.0); and Dermatology Life Quality Index overall score, 13.2 (6.5) and 12.0 (5.2), respectively. Overall, patients experienced CIU/ CSU for mean duration (SD) of 6.9 (9.1) years and adolescents for 3.2 (3.7) years, and received 5.0 (2.8) and 4.2 (2.3) previous CIU/CSU medications, respectively. Except for one adult, all patients received antihistamines. Concomitant medications included: H 2 -receptor antagonists (overall, 48.4%; adolescents, 48.7%); LTRA (34.5%; 35.9%) and steroids (45.7%; 33.3%). CONCLUSIONS: Understanding the clinical profile of CIU/CSU in adolescents will guide clinical practice.
Abstracts AB129SUNDAY
RATIONALE: Beta blockers(BB) have been associated with increased risk for severe anaphylactoid reaction(AR) from contrast media(CM); however, this was shown with intravenous CM(Arch Intern Med 1993;153:2033), prior to widespread use of low osmolar contrast media(LOCM), ACE inhibitors(ACE-I) and cardioselective BB. We assessed risk for AR with cardiac catheterization(CC) associated with BB or ACE-I exposure. METHODS: Patients who experienced adverse reactions during CC from January 2004-December 2013 were identified; 1-2 matched controls were assigned for each case. We analyzed AR rates in association with demographic variables, medication exposures (BB, ACE-I, Angiotensin receptor blockers, aspirin) and co-morbidities: cardiovascular disorders(CVD), asthma, atopy. RESULTS: We analyzed 71,782 CCs. Of these, severe 70 reactors were identified-46 (0.06%) fulfilled AR criteria. There were 35 mild-moderate and 11 severe AR (0.015%). There were no significant differences in age (61.3% vs 61.5%), gender (63% vs 64% male), CVD rate (78% vs 93%), exposure to BB (46% vs 51%, cardioselective: 81% vs 80%) and ACE-I (37.0% vs 37.2%) in cases vs. controls. Via multivariate logistic regression, BB exposure was not associated with greater AR frequency(p50.35) or severity (p50.40). Neither cardioselective BBs (p5 0.2) nor noncardioselective BB (p50.5) influenced AR severity. ACE-I had no effect on AR frequency (p50.35) or severity (p50.14). Lower AR frequency was associated with CVD (p50.01). CONCLUSIONS: In this case control-study, severe AR were rarely observed. Exposure to BB or ACE-I did not significantly influence AR frequency or severity; however, most BB were cardioselective. Our findings imply cardioselective BB or ACE-I suspension is not warranted in association with CC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.